MarketCap
Facebook
X
TelegramGeschäftsbericht 2024
hinzugefügt 21.02.2026
ProQR Therapeutics N.V. Betriebsaufwand 2011-2026 | PRQR
Betriebsaufwand Jährlich ProQR Therapeutics N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50 M | 41.4 M | 69.5 M | 59.6 M | 51.8 M | 59.4 M | 42.1 M | 42 M | 39.8 M | 27 M | 16.5 M | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 69.5 M | 16.5 M | 45.4 M |
Betriebsaufwand Vierteljährlich ProQR Therapeutics N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 18.3 M | 17.8 M | 15.7 M | 13.9 M | 12.2 M | 11.9 M | 11.1 M | 12 M | 16.7 M | 17.8 M | 14 M | 12.4 M | 15.2 M | - | 8.88 M | 8.64 M | - | - | - | 10.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 18.3 M | 8.64 M | 13.6 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
ADMA Biologics
ADMA
|
101 M | $ 16.55 | 1.04 % | $ 3.94 B |  USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Apellis Pharmaceuticals
APLS
|
948 M | $ 19.72 | -2.18 % | $ 2.49 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.82 | 4.04 % | $ 4.47 M |  China |
 |
Graybug Vision
GRAY
|
23.1 M | - | -11.23 % | $ 9.65 M | USA |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 165.57 | 0.93 % | $ 8.24 B | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.68 | -0.81 % | $ 1.1 B |  Canada |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
44.9 M | - | - | $ 521 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 59.1 | 0.97 % | $ 11.3 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.43 | -1.4 % | $ 1.39 B | Britain |
 |
Cabaletta Bio
CABA
|
74.7 M | $ 3.36 | 3.38 % | $ 3.92 M | USA |
 |
BridgeBio Pharma
BBIO
|
304 M | $ 64.6 | 0.11 % | $ 12.4 B | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Codexis
CDXS
|
31.5 M | $ 1.04 | 6.12 % | $ 76.3 M | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.83 | 0.63 % | $ 908 M |  Israel |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
425 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.76 | 6.71 % | $ 166 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
47.8 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
12.4 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
12 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
12 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
226 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Capricor Therapeutics
CAPR
|
49.3 M | $ 26.27 | 1.64 % | $ 703 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Certara
CERT
|
237 M | $ 7.29 | 0.69 % | $ 1.17 B | USA |
 |
CorMedix
CRMD
|
49 M | $ 7.06 | 2.17 % | $ 359 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Citius Pharmaceuticals
CTXR
|
42 M | $ 0.8 | 7.7 % | $ 5.38 M | USA |